The Association of the British Pharmaceutical Industry says work needs to be done to improve patient access to new drugs and make the market more accessible
The ABPI urges strong links with the EU and greater connectivity to new drugs for patients
The Association of the British Pharmaceutical Industry (ABPI) has called on the next government to implement a clear strategy improve healthcare investment in the UK.
The organisation recommends an increase in healthcare investment to the G7 average; and working to ensure that, in terms of patient access to new cost-effective medicines and vaccines, the UK is in the top quartile of the OECD by 2022.
The Group of Seven (G7) is an informal forum of countries representing around half of global economic output. The Organisation for Economic Co-operation and Development (OECD) is an intergovernmental economic organisation of 35 high income countries.
Currently, the UK spends a total of 9.9% of GDP on healthcare, placing them sixth out of the G7 nations for healthcare investment. Only Italy spends less.
“With an ageing population, this risks reducing the availability of care when we need it most,” says the ABPI's manifesto.
With an ageing population, this risks reducing the availability of care when we need it most.
ABPI adds that the governemnt needs to set out a clear plan on how patients can access the medicines they need on the naiton's National Health Service (NHS).
Some patients in the UK are still unable to obtain cost effective new treatments; Government analysis shows that, on average, for every 100 patients in comparable countries, just 18 patients in the UK receive access to a new medicine in its first year of launch.
The organisation claims that reforming the NHS to embrace new treatments is “crucial” to providing quality care to more patients within a sustainable budget.
Specific ABPI recommendations include:
The ABPI also urges the UK government to secure: co-operation with the EU on the regulation of medicines; access to the best talent in the region; predictable access to funding and collaboration for scientific research; and the ability to freely trade medicines / pharmaceutical supplies across borders.